SteadySharesSteadyShares
The market
MarketsDiscover
Follow the money
Smart MoneyPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Closed
SteadySharesMarketsDiscoverSmart MoneyMy WealthPoliticiansCryptoNews
/
Discover207940.KS
HealthcareKRXKRW

Samsung Biologics

₩00123456789,001234567890012345678900123456789,001234567890012345678900123456789.0012345678900123456789+4.7%
52w low (est.) ₩1,158,749.80₩1,717,010.20 52w high (est.)
Peers
Market data
Market cap
₩64.58T
52-week range
₩1,228,000.00 – ₩1,987,000.00
Beta (vs market)
0.20
Sector
Healthcare
Valuation
Forward P/E
28.9x
PEG ratio
1.97
Quality & efficiency
Moat score
90/100
Return on equity
18.3%
Profit margin
39.0%
Debt / equity
0.15
Growth & analysts
Revenue growth (YoY)
+25.8%
Analyst target
₩2,052,158.80
Target upside
+47.0%
Analysts covering
24

About Samsung Biologics

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.

Valuation

ValueGrowthProfitHealthIncome55QUALITY
Overall Rating
60
Buy
Buy
Moat Score90
DCF Intrinsic Value
Not covered by our valuation model yet.

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
₩64.58T
P/E Ratio
N/A
Dividend Yield
0.00%
Revenue Growth
+25.8%
Profit Margin
39.0%
ROE
18.3%
Debt / Equity
0.15
Beta
0.20
High Growth
vs Healthcare sector:Moat 90 vs 7Yield 0.00% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · 207940.KS